Media Centre

Press Releases: 2008 - 2009

09-16-2009
Piramal Life Sciences Makes Presentation on Breakthrough Molecule for Multi Drug Resistant Bacterial Infections at ICAAC Convention in the USA
Piramal Life Sciences Limited, made a presentation during the 49th Scientific Session of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) being convened at San Francisco, California, USA.

08-25-2009
Piramal Life Sciences completes Phase I Trials with a New Molecule for Type II Diabetes in Europe
Piramal Life Sciences Limited (PLSL), part of the Piramal Group of companies, today announced the completion of a Phase I study of a new, orally active glucoselowering compound, P1736, in The Netherlands

05-12-2009
Piramal Life Sciences Commences Phase I Trial on New Molecule for Diabetes - Metabolic Syndrome in Canada
Piramal Life Sciences Ltd. (PLSL) has commenced Phase I trial of a new experimental drug molecule P2202 for diabetes-metabolic syndrome in Canada.

05-12-2009
Piramal Life Sciences receives DCGI Approval to conduct Phase I/II Combination Trials of P276 for Pancreatic, and Head and Neck Cancer in India
Piramal Life Sciences Limited, part of the Piramal Group of companies, has received regulatory approval by Drug Controller General of India (DCGI) for the initiation of two phase-I/II combination studies.

01-15-2009
Piramal Life Sciences begins Phase II trial of P276 for mantle Cell Lymphoma
Piramal Life Sciences Limited (PLSL) announced today that it has started phase II trial in USA for it’s lead cancer compound P 276-00 to treat Mantle cell Lymphoma (MCL) and it is the second IND approved by the US FDA for this compound.

10-18-2008
Piramal Life Sciences begins Phase II trial of P276 for head and neck cancer
Piramal Life Sciences Limited has announced that a Phase II study for its lead cancer molecule P276 for the treatment of head and neck cancer has been initiated in India.

10-13-2008
Piramal Life Sciences receives DCGI Approval to conduct Phase I Trial of New Cancer Molecule P-1446A-05 in India.
Piramal Life Sciences Limited, part of the Piramal Group of companies, has received regulatory approval for the initiation of a phase-I study in India by Drug Controller General of India (DCGI) of a new cancer compound, P-1446A-05.

09-28-2008
Piramal Life Sciences Obtains Approval for Initiation of Phase I Trials of New Cancer Molecule P-1446A-05 in Canada
Piramal Life Sciences Limited, part of the Piramal Group of companies, has received regulatory approval for the initiation of a Phase I study of a new cancer compound, P-1446A-05, in Canada.

06-12-2008
A Press Note: Industry –University/National institutes Partnership
A DBT Mission Programme on: "Screening for Bio-molecules from microbial diversity collected from different ecological niches"

06-09-2008
Piramal Life Sciences Makes Oral Presentation on Breakthrough Molecule for Type II Diabetes at ADA Convention
Piramal Life Sciences Limited, part of the Piramal Group of companies, today made an oral presentation during the 68th Scientific Session of the American Diabetes Association (ADA) being convened at San Francisco, California, USA

05-30-2008
Piramal Life Sciences Limited now a listed company
Piramal Life Sciences Limited ("PLSL"), a research and development company recently demerged from Piramal Healthcare Limited ("PHL"), previously known as Nicholas Piramal India Limited ("NPIL"), was today listed